Study Cohorts and Enrollment.
HRR mutation-positive
EVENTS
*An interim analysis (IA) was planned with ~70% of the total required events. The HRRm cohort would be stopped for efficacy if the pre-specified efficacy boundary was crossed (P ≤ 0.003). As the efficacy boundary was crossed at the IA rPFS, this became the final analysis. Survival and safety follow-up is continuing. All other endpoints are final. HRR denotes homologous recombination repair, HRRm HRR mutation-positive, and rPFS radiographic progression-free survival.
